Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We ranked the 10 best commercials from the 2025 Super Bowl and found them online so you can judge them for yourself.

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

Welcome to the Wall Street Week newsletter, bringing you stories of capitalism about things you need to know, but even more ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.